On 12 Nov 2026 Becton Dickinson closed at $215.71, +44.1% this year; market cap $59.12bn, P/E 51.7.
Health Care · Health Care Equipment · NYSE · United States
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
| Market cap | $59.12bn |
| P/E (trailing) | 51.7 |
| EPS (TTM) | $4.17 |
| Beta | 0.28 |
| Dividend | $4.24 |
| Dividend yield | 1.97% |
| Ex-dividend date | 10 Dec 2026 |
| Latest report | 5 Nov 2026 |
| Next earnings | 4 Feb 2027 |
| YTD | +44.1% |
| 1Y | +46.4% |
| 3Y | +7.4% |
| 5Y | +4.8% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2026 | $19.46bn | $1.15bn | $2.93bn |
| 2025 | $21.84bn | $1.68bn | $2.67bn |
| 2024 | $20.18bn | $1.71bn | $3.07bn |
| 2023 | $19.37bn | $1.48bn | $2.12bn |
| 2022 | $18.87bn | $1.78bn | $1.66bn |
We publish no single base value for Becton Dickinson. Our valuation methods put it between $96.67 and $100.33 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.